(R)-(-)-3-Phenyl-3-(4-piperidinyl)-2,6-piperidinedione | 115216-88-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-(-)-3-Phenyl-3-(4-piperidinyl)-2,6-piperidinedione
• 英文别名: (R)-3-phenyl-[3,4'-bipiperidine]-2,6-dione；(3R)-3-phenyl-3-piperidin-4-ylpiperidine-2,6-dione
• CAS: 115216-88-1
• 化学式: C₁₆H₂₀N₂O₂
• 分子量: 272.347
• InChiKey: WCKABEIXAFZEIO-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-(-)-3-Phenyl-3-(4-piperidinyl)-2,6-piperidinedione 生成 (R)-3-Phenyl-3-<1-<<4-(trimethylsilyl)phenyl>methyl>-4-piperidinyl>-2,6-piperidinedione
  参考文献：
  名称：

  WILSON, ALAN A.;DANNALS, ROBERT F.;RAVERT, HAYDEN T.;FROST, J. JAMES;WAGN+, J. MED. CHEM., 32,(1989) N, C. 1057-1062

  摘要：

  DOI：
• 作为产物：
  描述：

  Levetimide 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 以93.3%的产率得到(R)-(-)-3-Phenyl-3-(4-piperidinyl)-2,6-piperidinedione
  参考文献：
  名称：

  WO2007/90826

  摘要：

  公开号：

文献信息

• WO2007/90826
  申请人：——

  公开号：——

  公开（公告）日：——
• WILSON, ALAN A.;DANNALS, ROBERT F.;RAVERT, HAYDEN T.;FROST, J. JAMES;WAGN+, J. MED. CHEM., 32,(1989) N, C. 1057-1062
  作者：WILSON, ALAN A.、DANNALS, ROBERT F.、RAVERT, HAYDEN T.、FROST, J. JAMES、WAGN+

  DOI：——

  日期：——
• DANNALS R. F.; LANGSTROM B.; FROST J. J.; RAVERT H. T.; WILSON A. A.; WAG+, J. LABELLED COMPOUNDS AND RADIOPHARM., 23,(1986) N 10-12, 1407-1409
  作者：DANNALS R. F.、 LANGSTROM B.、 FROST J. J.、 RAVERT H. T.、 WILSON A. A.、 WAG+

  DOI：——

  日期：——
• PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP1984349A1

  公开（公告）日：2008-10-29
• Piperidine Derivatives as Cxcr3 Receptor Antagonists
  申请人：Coesemans Erwin

  公开号：US20090030039A1

  公开（公告）日：2009-01-29

  The present invention relates to a compound of formula (I) a N-oxide thereof, a pharmaceutically acceptable salt thereof, a stereochemically isomeric form thereof or a solvate thereof, wherein X represents N or CH; Y and Z each independently represent C(═O) or CH 2 provided that at least one of Y and Z represents C(═O); R 1 represents CH(R 4 )-aryl or CH(R 4 )-heteroaryl; R 2 represents aryl 2 or heteroaryl; R 3 represents hydrogen; C 1-4 alkylcarbonyl; C 1-6 alkyl optionally substituted with C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxycarbonyl or aryl 1 ; provided that when Y and Z each represent C(═O), X represents CH, R 3 represents hydrogen, R 4 represents hydrogen, and R 2 represents unsubstituted pyridyl or phenyl optionally substituted with one halo or with one C 1-4 alkyloxy or with one or two C 1-4 alkyl, then aryl in the definition of R 1 is other than phenyl substituted with one halo or with one or two C 1-4 alkyl; and provided that when Y and Z each represent C(═O), X represents CH, R 3 represents hydrogen, and R 2 represents unsubstituted pyridyl or phenyl optionally substituted with one halo or with one C 1-4 alkyloxy or with one or two C 1-4 alkyl, then heteroaryl in the definition of R 1 is other than unsubstituted thienyl or unsubstituted pyridyl. The present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for preventing or treating a disease mediated through activation of the CXCR3 receptor; to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.